TEN is most commonly drug induced. However, the disorder has other potential etiologies, including infection, malignancy, and vaccinations (see Etiology). TEN is idiosyncratic, and its occurrence is not easily predicted.

Some authors believe that Stevens-Johnson syndrome (SJS; also known as erythema multiforme major) is a manifestation of the same process involved in TEN, with the latter involving more extensive necrotic epidermal detachment. TEN involves more than 30% of the body surface, whereas SJS involves less than 10% (see Differentials).

A classification system, based largely on the extent of epidermal detachment and morphology of the skin lesions, aids in differentiating opposite spectrums of the same disease entity.
[1] This system comprises the following:

TEN with spots

TEN without spots

Overlap Stevens-Johnson syndrome and TEN (SJS-TEN)

TEN with spots is defined as widespread, irregularly shaped erythematous or purpuric macules with blistering that occurs on all or part of the macule. Blisters become more confluent and result in detachment of the epidermis and erosions on greater than 30% of the body surface area. Mucosal surfaces are usually involved.

TEN without spots is defined as widespread, large areas of erythema with no discrete lesions. Epidermal detachment is greater than 10% of the body surface area. Mucosal surfaces are usually involved.

Overlap Stevens-Johnson syndrome and TEN (SJS-TEN) is characterized by widespread, irregularly shaped erythematous or purpuric macules with blistering that occurs on all or part of the macule. Blisters become confluent and result in detachment of the epidermis and erosions on 10-29% of the body surface area.

TEN is a clinical diagnosis, confirmed by histopathologic analysis of lesional skin (see Clinical and Workup). The mainstay of treatment is supportive care until the epithelium regenerates. Early transfer of patients to a burn or intensive care unit has been shown to reduce the risk of infection, mortality rate, and length of hospitalization (see Treatment).

Historical background

Alan Lyell provided an early description of TEN in 1956, describing the condition as "an eruption resembling scalding of the skin."
[2] This dermatologic condition is characterized by extensive epidermal loss suggestive of severe scalding. In that same year, Lang and Walker reported a case of TEN.
[3] The disorder was originally described by Debre et al in 1939 in French as l'erythrodermie bulleuses avec epidermolyse.
[4]

Lyell later reclassified the conditions of 2 of his patients as having staphylococcal scalded skin syndrome,
[5] which is due to Staphylococcus aureus infection rather than to a probable drug hypersensitivity-type reaction. Histopathologic analysis of the skin remains the main tool for discrimination between the two conditions.

Patient education

Patients who have had TEN must be counseled regarding the likely causative medication or agent, and they must be advised to avoid these medications and those of the same or similar classes in the future. Cross-reactivity may occur with agents that chemically resemble the causative agent. Patients must call a pharmacist whenever they start a new prescription.

Genetic factors are suspected in drug-induced blistering disorders, and blood relatives of the patient also should not use the suspected drug.

Pathophysiology

The pathophysiology of TEN has not been fully elucidated; however, various theories have received wide acceptance. TEN is believed to be an immune-related cytotoxic reaction aimed at destroying keratinocytes that express a foreign antigen.

TEN mimics a hypersensitivity reaction, with its characteristic delayed reaction to an initial exposure and an increasingly rapid reaction with repeated exposure.

The widespread epidermolysis and blistering of TEN results from keratinocyte apoptosis—an organized series of biochemical reactions leading to cell changes and cell death.
[6] However, the number of inflammatory T cells in the skin of patients with TEN is variable and perhaps too low to explain the widespread destruction.
[7]

There is evidence supporting several immunopathologic pathways leading to keratinocyte apoptosis in TEN, including the following:

Fas ligand activation on keratinocyte membranes leading to death receptor–mediated apoptosis
[8]

Precisely how the inciting agent triggers the proposed pathways is yet to be elucidated.

Previous

Next:

Etiology

TEN can be induced by drugs or infection or can be idiopathic. Medications are the major precipitating cause. Numerous medications have been implicated,
[13] including antibiotics, antiepileptic drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), ampicillin, allopurinol, corticosteroids (topical and systemic), and the antiretroviral drugs nevirapine and abacavir.
[14, 15]

TEN in patients taking anticonvulsants has most often been reported within 2 months of starting the drug. However, some cases associated with long-term use have been reported.

NSAIDs associated with TEN include the following:

Phenylbutazone and oxybutazone - Implicated most commonly, although they are no longer available in the United States

Oxicams (eg, piroxicam, tenoxicam) - Implicated more often than other NSAIDs

Ibuprofen

Indomethacin

Sulindac

Tolmetin

With allopurinol, risk is not constant over time. Patients have a 5.5 relative risk. However, during the first 2 months of therapy, the relative risk is 52, and the long-term therapy risk is 0.5.

No laboratory test is able to confirm a specific drug etiology. A causal link is suggested when TEN occurs during the first 4 weeks of medication therapy, usually between 1 and 3 weeks. Drugs with longer half-lives and those with circulating active metabolites may result in more fulminant disease.

Epidemiology

In the United States, the annual frequency of TEN is reported to be 0.22-1.23 cases per 100,000 population. In the HIV-positive population, the incidence of TEN increases to 1 case per thousand per year.
[19]

Worldwide, the average annual incidence of TEN is 0.4-1.3 cases per million population.
[20] In 1992, the cumulative incidence of TEN and SJS in Germany was 1.9 cases per million population. A French survey of dermatologists and health care facilities reported an annual incidence of 1 case per million population.

Race-, sex-, and age-related demographics

A genetic predilection toward carbamazepine-induced TEN has been observed in HLA-B*1502–positive Han Chinese patients.
[21] The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiating carbamazepine in patients of Asian ancestry.
[22]

For unclear reasons, TEN appears to have a predilection for females. The female-to-male ratio is 1.5:1.
[23]

TEN may occur in all age groups; however, the mean age of patients with TEN is reported to be between 46 and 63 years. Infection is more commonly implicated as an etiology in children, whereas medication exposure is more common in adults. Elderly persons may be at greater risk because of their tendency to use multiple medications.

Previous

Next:

Prognosis

The estimated mortality associated with TEN varies widely in different reports, from 10-70%. Outcome depends in part on the quality of care and the rapidity with which treatment is initiated.

Septicemia and multisystem organ failure are the primary causes of death. Epithelial loss results in vulnerability to bacterial and fungal infections. Sloughing of stratified epithelium of mucosal membranes can result in GI hemorrhage, respiratory failure, ocular abnormalities, and genitourinary lesions. Significant fluid loss from extensive skin exfoliation and an inability to tolerate oral intake can lead to hypovolemia, acute tubular necrosis, and shock.

Age, extent of epidermal involvement, and serum urea level are said to be the most important prognostic factors in TEN.
[24] Mortality rates in children are much lower than in adults.
[25] Elderly patients have a poor prognosis.

Other negative prognostic factors include the following:

Elevated blood urea nitrogen (BUN) and serum creatinine levels

Respiratory failure

Multiple drugs

Thrombocytopenia

Lymphopenia

Neutropenia

Leukopenia

Sepsis

Severity-of-illness score

A severity-of-illness score that estimates the risk of death in TEN (SCORTEN) has been developed and validated.
[26] Each of the following independent prognostic factors is given a score of 1:

Age >40 years

Heart rate >120 beats per minute

Cancer or hematologic malignancy

Involved body surface area >10%

Blood urea nitrogen level >10 mmol/L (28 mg/dL)

Serum bicarbonate level < 20 mmol/L (20 mEq/L)

Blood glucose level >14 mmol/L (252 mg/dL)

The number of positive criteria and the corresponding mortality rates are as follows:

0: 1 to 3%

2: 12%

3: 35%

4: 58%

5 or more: 90%

Sequelae

Major sequelae are generally limited to the affected organ systems (ie, the skin and mucosal membranes).

Cutaneous sequelae of TEN include the following:

Changes in skin pigment (hypopigmentation or hyperpigmentation; sun exposure must be avoided for several months because ultraviolet light can worsen hyperpigmentation; sunblock is recommended)

Nail loss and nail dystrophy

Hypohidrosis (inability to sweat)

Scarring, alopecia, and hypertrophic scarring

Dermal desiccation, causing deep dermal wounds

Chronic xerostomia

Esophageal strictures

Vulvovaginal synechiae

Phimosis

Chronic erosion of the mouth and genitalia

Ocular complications generally result from abnormal keratinization of the tarsal conjunctiva. A Sjogrenlike syndrome with decreased lacrimal secretion causes dry eye and predisposes to corneal abrasions and corneal scarring with neovascularization. In addition, patients have been reported to have palpebral synechiae, entropion, or symblepharon (adhesion of the eyelids).
[27]

A study by Power and colleagues found that 50% of patients with TEN developed ocular complications.
[28] Patients treated with steroids fared no better than those treated without steroids. Therefore, TEN remains a common cause of visual loss in a significant number of patients. Ultimately, 5-9% of patients can become blind as a result of some of these complications.

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration